nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—head and neck cancer	0.599	1	CtDrD
Sorafenib—ABCC4—Fluorouracil—head and neck cancer	0.0339	0.176	CbGbCtD
Sorafenib—ABCC2—Vinblastine—head and neck cancer	0.0187	0.0972	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—head and neck cancer	0.0182	0.0949	CbGbCtD
Sorafenib—CYP2D6—Hydroxyurea—head and neck cancer	0.0162	0.0844	CbGbCtD
Sorafenib—ABCC2—Docetaxel—head and neck cancer	0.0154	0.0801	CbGbCtD
Sorafenib—ABCG2—Docetaxel—head and neck cancer	0.0139	0.0725	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—head and neck cancer	0.0103	0.0535	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0103	0.0535	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—head and neck cancer	0.00972	0.0505	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—head and neck cancer	0.00772	0.0401	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—head and neck cancer	0.00752	0.0391	CbGbCtD
Sorafenib—CYP2C9—Fluorouracil—head and neck cancer	0.00678	0.0353	CbGbCtD
Sorafenib—ABCB1—Vinblastine—head and neck cancer	0.00609	0.0317	CbGbCtD
Sorafenib—CYP2D6—Vinblastine—head and neck cancer	0.00574	0.0299	CbGbCtD
Sorafenib—ABCB1—Docetaxel—head and neck cancer	0.00502	0.0261	CbGbCtD
Sorafenib—Radiation pneumonitis—Docetaxel—head and neck cancer	0.00392	0.0682	CcSEcCtD
Sorafenib—CYP3A4—Vinblastine—head and neck cancer	0.00365	0.019	CbGbCtD
Sorafenib—Recall phenomenon—Hydroxyurea—head and neck cancer	0.00314	0.0545	CcSEcCtD
Sorafenib—CYP3A4—Docetaxel—head and neck cancer	0.00301	0.0157	CbGbCtD
Sorafenib—Skin cancer—Hydroxyurea—head and neck cancer	0.00175	0.0305	CcSEcCtD
Sorafenib—Radiation recall reaction (dermatologic)—Docetaxel—head and neck cancer	0.00172	0.0299	CcSEcCtD
Sorafenib—RET—parathyroid gland—head and neck cancer	0.00164	0.0335	CbGeAlD
Sorafenib—Ischaemia—Vinblastine—head and neck cancer	0.00163	0.0284	CcSEcCtD
Sorafenib—Recall phenomenon—Docetaxel—head and neck cancer	0.00163	0.0283	CcSEcCtD
Sorafenib—Gastrointestinal perforation—Docetaxel—head and neck cancer	0.00108	0.0188	CcSEcCtD
Sorafenib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.000982	0.0171	CcSEcCtD
Sorafenib—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.000925	0.0161	CcSEcCtD
Sorafenib—MKNK2—hair follicle—head and neck cancer	0.00076	0.0155	CbGeAlD
Sorafenib—MKNK1—hair follicle—head and neck cancer	0.000751	0.0153	CbGeAlD
Sorafenib—MAPK15—thyroid gland—head and neck cancer	0.000704	0.0144	CbGeAlD
Sorafenib—CDKL2—head—head and neck cancer	0.000693	0.0142	CbGeAlD
Sorafenib—RALBP1—hair follicle—head and neck cancer	0.000687	0.014	CbGeAlD
Sorafenib—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.000666	0.0116	CcSEcCtD
Sorafenib—RAF1—hair follicle—head and neck cancer	0.000649	0.0133	CbGeAlD
Sorafenib—MAPK15—head—head and neck cancer	0.000624	0.0127	CbGeAlD
Sorafenib—Ascites—Docetaxel—head and neck cancer	0.000622	0.0108	CcSEcCtD
Sorafenib—CDK7—connective tissue—head and neck cancer	0.000618	0.0126	CbGeAlD
Sorafenib—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000585	0.0102	CcSEcCtD
Sorafenib—Lymphopenia—Docetaxel—head and neck cancer	0.000552	0.00959	CcSEcCtD
Sorafenib—Neoplasm—Vinblastine—head and neck cancer	0.000539	0.00937	CcSEcCtD
Sorafenib—HIPK3—connective tissue—head and neck cancer	0.000523	0.0107	CbGeAlD
Sorafenib—Skin exfoliation—Hydroxyurea—head and neck cancer	0.000519	0.00902	CcSEcCtD
Sorafenib—KIT—exocrine gland—head and neck cancer	0.000513	0.0105	CbGeAlD
Sorafenib—Mucosal inflammation—Docetaxel—head and neck cancer	0.00051	0.00887	CcSEcCtD
Sorafenib—EPHX2—parotid gland—head and neck cancer	0.000509	0.0104	CbGeAlD
Sorafenib—RET—neck—head and neck cancer	0.000497	0.0102	CbGeAlD
Sorafenib—Neoplasm—Hydroxyurea—head and neck cancer	0.000492	0.00854	CcSEcCtD
Sorafenib—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.000487	0.00846	CcSEcCtD
Sorafenib—TIE1—epithelium—head and neck cancer	0.000464	0.00947	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—head and neck cancer	0.000452	0.00923	CbGeAlD
Sorafenib—FLT3—connective tissue—head and neck cancer	0.000445	0.00908	CbGeAlD
Sorafenib—Embolism—Docetaxel—head and neck cancer	0.00044	0.00765	CcSEcCtD
Sorafenib—Hepatic failure—Hydroxyurea—head and neck cancer	0.000439	0.00763	CcSEcCtD
Sorafenib—FLT1—neck—head and neck cancer	0.000438	0.00894	CbGeAlD
Sorafenib—RAF1—neck—head and neck cancer	0.000436	0.00889	CbGeAlD
Sorafenib—MAP3K7—parotid gland—head and neck cancer	0.000429	0.00875	CbGeAlD
Sorafenib—Renal failure acute—Hydroxyurea—head and neck cancer	0.000428	0.00743	CcSEcCtD
Sorafenib—MAPK11—thyroid gland—head and neck cancer	0.000417	0.00852	CbGeAlD
Sorafenib—MKNK2—parotid gland—head and neck cancer	0.000415	0.00848	CbGeAlD
Sorafenib—CDK7—thyroid gland—head and neck cancer	0.000411	0.00838	CbGeAlD
Sorafenib—Haemoglobin decreased—Docetaxel—head and neck cancer	0.000411	0.00713	CcSEcCtD
Sorafenib—MAP3K7—saliva-secreting gland—head and neck cancer	0.000411	0.00838	CbGeAlD
Sorafenib—TAOK2—thyroid gland—head and neck cancer	0.000407	0.00832	CbGeAlD
Sorafenib—AURKC—thyroid gland—head and neck cancer	0.000404	0.00825	CbGeAlD
Sorafenib—Interstitial lung disease—Docetaxel—head and neck cancer	0.000399	0.00694	CcSEcCtD
Sorafenib—MKNK2—saliva-secreting gland—head and neck cancer	0.000398	0.00812	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—head and neck cancer	0.000391	0.00798	CbGeAlD
Sorafenib—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.000389	0.00675	CcSEcCtD
Sorafenib—KIT—mouth—head and neck cancer	0.000384	0.00784	CbGeAlD
Sorafenib—FLT4—epithelium—head and neck cancer	0.000383	0.00783	CbGeAlD
Sorafenib—RALBP1—parotid gland—head and neck cancer	0.000375	0.00766	CbGeAlD
Sorafenib—KDR—neck—head and neck cancer	0.00037	0.00756	CbGeAlD
Sorafenib—MAPK11—head—head and neck cancer	0.00037	0.00756	CbGeAlD
Sorafenib—Pleural effusion—Docetaxel—head and neck cancer	0.000369	0.00641	CcSEcCtD
Sorafenib—MKNK2—connective tissue—head and neck cancer	0.000366	0.00746	CbGeAlD
Sorafenib—CDK7—head—head and neck cancer	0.000364	0.00744	CbGeAlD
Sorafenib—RALBP1—saliva-secreting gland—head and neck cancer	0.000359	0.00733	CbGeAlD
Sorafenib—AURKC—head—head and neck cancer	0.000359	0.00732	CbGeAlD
Sorafenib—FLT1—parotid gland—head and neck cancer	0.000357	0.00728	CbGeAlD
Sorafenib—Breast disorder—Hydroxyurea—head and neck cancer	0.000357	0.0062	CcSEcCtD
Sorafenib—RET—connective tissue—head and neck cancer	0.000357	0.00728	CbGeAlD
Sorafenib—ZAK—thyroid gland—head and neck cancer	0.000355	0.00724	CbGeAlD
Sorafenib—RAF1—parotid gland—head and neck cancer	0.000355	0.00724	CbGeAlD
Sorafenib—EPHB6—parotid gland—head and neck cancer	0.000353	0.0072	CbGeAlD
Sorafenib—Myocardial ischaemia—Docetaxel—head and neck cancer	0.000351	0.00611	CcSEcCtD
Sorafenib—Rhinorrhoea—Docetaxel—head and neck cancer	0.000349	0.00606	CcSEcCtD
Sorafenib—HIPK3—thyroid gland—head and neck cancer	0.000347	0.00709	CbGeAlD
Sorafenib—MKNK2—epithelium—head and neck cancer	0.000347	0.00708	CbGeAlD
Sorafenib—FLT1—saliva-secreting gland—head and neck cancer	0.000342	0.00698	CbGeAlD
Sorafenib—RAF1—saliva-secreting gland—head and neck cancer	0.00034	0.00694	CbGeAlD
Sorafenib—RET—epithelium—head and neck cancer	0.000338	0.00691	CbGeAlD
Sorafenib—EPHB6—saliva-secreting gland—head and neck cancer	0.000338	0.0069	CbGeAlD
Sorafenib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000335	0.00581	CcSEcCtD
Sorafenib—EPHA6—head—head and neck cancer	0.000332	0.00678	CbGeAlD
Sorafenib—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000329	0.00571	CcSEcCtD
Sorafenib—KIT—neck—head and neck cancer	0.000328	0.0067	CbGeAlD
Sorafenib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000327	0.00568	CcSEcCtD
Sorafenib—Myocardial infarction—Vinblastine—head and neck cancer	0.000327	0.00568	CcSEcCtD
Sorafenib—FLT3—lymphoid tissue—head and neck cancer	0.000325	0.00664	CbGeAlD
Sorafenib—TIE1—thyroid gland—head and neck cancer	0.000325	0.00663	CbGeAlD
Sorafenib—PDGFRB—neck—head and neck cancer	0.000321	0.00654	CbGeAlD
Sorafenib—Neutropenia—Hydroxyurea—head and neck cancer	0.000319	0.00554	CcSEcCtD
Sorafenib—MAP3K7—trachea—head and neck cancer	0.000317	0.00646	CbGeAlD
Sorafenib—ZAK—head—head and neck cancer	0.000315	0.00643	CbGeAlD
Sorafenib—FLT1—connective tissue—head and neck cancer	0.000314	0.00641	CbGeAlD
Sorafenib—Bone disorder—Docetaxel—head and neck cancer	0.000313	0.00544	CcSEcCtD
Sorafenib—RAF1—connective tissue—head and neck cancer	0.000312	0.00637	CbGeAlD
Sorafenib—BRAF—thyroid gland—head and neck cancer	0.000311	0.00635	CbGeAlD
Sorafenib—MKNK2—trachea—head and neck cancer	0.000307	0.00626	CbGeAlD
Sorafenib—Drug interaction—Docetaxel—head and neck cancer	0.000305	0.00529	CcSEcCtD
Sorafenib—Infestation—Hydroxyurea—head and neck cancer	0.000304	0.00529	CcSEcCtD
Sorafenib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000304	0.00529	CcSEcCtD
Sorafenib—MAP3K19—head—head and neck cancer	0.000302	0.00616	CbGeAlD
Sorafenib—KDR—parotid gland—head and neck cancer	0.000302	0.00616	CbGeAlD
Sorafenib—MAP2K5—parotid gland—head and neck cancer	0.000302	0.00616	CbGeAlD
Sorafenib—Haemoglobin—Vinblastine—head and neck cancer	0.000301	0.00523	CcSEcCtD
Sorafenib—Haemorrhage—Vinblastine—head and neck cancer	0.000299	0.0052	CcSEcCtD
Sorafenib—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000299	0.00519	CcSEcCtD
Sorafenib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000298	0.00518	CcSEcCtD
Sorafenib—FLT1—epithelium—head and neck cancer	0.000298	0.00609	CbGeAlD
Sorafenib—EPHX2—thyroid gland—head and neck cancer	0.000297	0.00607	CbGeAlD
Sorafenib—Stomatitis—Hydroxyurea—head and neck cancer	0.000297	0.00515	CcSEcCtD
Sorafenib—RAF1—epithelium—head and neck cancer	0.000296	0.00605	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—head and neck cancer	0.000295	0.00603	CbGeAlD
Sorafenib—PDGFRA—connective tissue—head and neck cancer	0.000294	0.00601	CbGeAlD
Sorafenib—Cardiac failure—Fluorouracil—head and neck cancer	0.000291	0.00506	CcSEcCtD
Sorafenib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000289	0.0059	CbGeAlD
Sorafenib—KDR—saliva-secreting gland—head and neck cancer	0.000289	0.0059	CbGeAlD
Sorafenib—TIE1—head—head and neck cancer	0.000288	0.00588	CbGeAlD
Sorafenib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000288	0.005	CcSEcCtD
Sorafenib—Blood pressure increased—Docetaxel—head and neck cancer	0.000283	0.00491	CcSEcCtD
Sorafenib—RALBP1—trachea—head and neck cancer	0.000277	0.00566	CbGeAlD
Sorafenib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000275	0.00477	CcSEcCtD
Sorafenib—Influenza like illness—Docetaxel—head and neck cancer	0.000274	0.00477	CcSEcCtD
Sorafenib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000273	0.00475	CcSEcCtD
Sorafenib—Skin exfoliation—Docetaxel—head and neck cancer	0.00027	0.00469	CcSEcCtD
Sorafenib—FLT4—thyroid gland—head and neck cancer	0.000268	0.00547	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—head and neck cancer	0.000267	0.00546	CbGeAlD
Sorafenib—KIT—parotid gland—head and neck cancer	0.000267	0.00546	CbGeAlD
Sorafenib—KDR—connective tissue—head and neck cancer	0.000265	0.00542	CbGeAlD
Sorafenib—Neuropathy—Docetaxel—head and neck cancer	0.000265	0.00461	CcSEcCtD
Sorafenib—Alopecia—Vinblastine—head and neck cancer	0.000265	0.0046	CcSEcCtD
Sorafenib—FGFR1—thyroid gland—head and neck cancer	0.000265	0.0054	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—head and neck cancer	0.000264	0.00539	CbGeAlD
Sorafenib—FLT1—trachea—head and neck cancer	0.000264	0.00538	CbGeAlD
Sorafenib—RAF1—trachea—head and neck cancer	0.000262	0.00535	CbGeAlD
Sorafenib—PDGFRB—parotid gland—head and neck cancer	0.000261	0.00533	CbGeAlD
Sorafenib—RET—lymphoid tissue—head and neck cancer	0.000261	0.00532	CbGeAlD
Sorafenib—EPHB6—trachea—head and neck cancer	0.000261	0.00532	CbGeAlD
Sorafenib—Dry skin—Fluorouracil—head and neck cancer	0.00026	0.00453	CcSEcCtD
Sorafenib—MAPK11—lymph node—head and neck cancer	0.000259	0.00529	CbGeAlD
Sorafenib—CSF1R—connective tissue—head and neck cancer	0.000259	0.00529	CbGeAlD
Sorafenib—KIT—saliva-secreting gland—head and neck cancer	0.000256	0.00523	CbGeAlD
Sorafenib—Neoplasm—Docetaxel—head and neck cancer	0.000255	0.00444	CcSEcCtD
Sorafenib—CDK7—lymph node—head and neck cancer	0.000255	0.00521	CbGeAlD
Sorafenib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000254	0.00441	CcSEcCtD
Sorafenib—TAOK2—lymph node—head and neck cancer	0.000253	0.00517	CbGeAlD
Sorafenib—KDR—epithelium—head and neck cancer	0.000252	0.00514	CbGeAlD
Sorafenib—AURKC—lymph node—head and neck cancer	0.000251	0.00513	CbGeAlD
Sorafenib—MAP3K7—thyroid gland—head and neck cancer	0.000251	0.00511	CbGeAlD
Sorafenib—PDGFRB—saliva-secreting gland—head and neck cancer	0.00025	0.0051	CbGeAlD
Sorafenib—Angiopathy—Hydroxyurea—head and neck cancer	0.000248	0.00431	CcSEcCtD
Sorafenib—PDGFRA—trachea—head and neck cancer	0.000247	0.00504	CbGeAlD
Sorafenib—Dysphagia—Fluorouracil—head and neck cancer	0.000246	0.00427	CcSEcCtD
Sorafenib—MKNK2—thyroid gland—head and neck cancer	0.000243	0.00496	CbGeAlD
Sorafenib—Alopecia—Hydroxyurea—head and neck cancer	0.000241	0.00419	CcSEcCtD
Sorafenib—Anaemia—Vinblastine—head and neck cancer	0.000241	0.00419	CcSEcCtD
Sorafenib—MKNK1—thyroid gland—head and neck cancer	0.00024	0.00489	CbGeAlD
Sorafenib—FLT4—head—head and neck cancer	0.000238	0.00486	CbGeAlD
Sorafenib—Erythema—Hydroxyurea—head and neck cancer	0.000238	0.00413	CcSEcCtD
Sorafenib—RET—thyroid gland—head and neck cancer	0.000237	0.00483	CbGeAlD
Sorafenib—KIT—connective tissue—head and neck cancer	0.000235	0.0048	CbGeAlD
Sorafenib—Leukopenia—Vinblastine—head and neck cancer	0.000233	0.00405	CcSEcCtD
Sorafenib—PDGFRB—connective tissue—head and neck cancer	0.00023	0.00469	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—head and neck cancer	0.00023	0.00469	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—head and neck cancer	0.000228	0.00466	CbGeAlD
Sorafenib—Hepatic failure—Docetaxel—head and neck cancer	0.000228	0.00397	CcSEcCtD
Sorafenib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000226	0.00393	CcSEcCtD
Sorafenib—Hypertension—Vinblastine—head and neck cancer	0.000225	0.00391	CcSEcCtD
Sorafenib—KIT—epithelium—head and neck cancer	0.000223	0.00456	CbGeAlD
Sorafenib—KDR—trachea—head and neck cancer	0.000223	0.00455	CbGeAlD
Sorafenib—MAP2K5—trachea—head and neck cancer	0.000223	0.00455	CbGeAlD
Sorafenib—ZAK—lymph node—head and neck cancer	0.00022	0.0045	CbGeAlD
Sorafenib—Pneumonia—Fluorouracil—head and neck cancer	0.00022	0.00383	CcSEcCtD
Sorafenib—Anaemia—Hydroxyurea—head and neck cancer	0.00022	0.00382	CcSEcCtD
Sorafenib—RALBP1—thyroid gland—head and neck cancer	0.000219	0.00448	CbGeAlD
Sorafenib—Infestation—Fluorouracil—head and neck cancer	0.000219	0.0038	CcSEcCtD
Sorafenib—Infestation NOS—Fluorouracil—head and neck cancer	0.000219	0.0038	CcSEcCtD
Sorafenib—PDGFRB—epithelium—head and neck cancer	0.000218	0.00445	CbGeAlD
Sorafenib—CSF1R—trachea—head and neck cancer	0.000217	0.00444	CbGeAlD
Sorafenib—STK10—lymphoid tissue—head and neck cancer	0.000217	0.00444	CbGeAlD
Sorafenib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000216	0.00375	CcSEcCtD
Sorafenib—HIPK3—lymph node—head and neck cancer	0.000216	0.0044	CbGeAlD
Sorafenib—MKNK2—head—head and neck cancer	0.000215	0.0044	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—head and neck cancer	0.000215	0.00439	CbGeAlD
Sorafenib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000215	0.00373	CcSEcCtD
Sorafenib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000215	0.00373	CcSEcCtD
Sorafenib—Stomatitis—Fluorouracil—head and neck cancer	0.000213	0.00371	CcSEcCtD
Sorafenib—Leukopenia—Hydroxyurea—head and neck cancer	0.000213	0.0037	CcSEcCtD
Sorafenib—MKNK1—head—head and neck cancer	0.000213	0.00434	CbGeAlD
Sorafenib—Cardiac failure—Docetaxel—head and neck cancer	0.00021	0.00365	CcSEcCtD
Sorafenib—RET—head—head and neck cancer	0.00021	0.00429	CbGeAlD
Sorafenib—FLT1—thyroid gland—head and neck cancer	0.000209	0.00426	CbGeAlD
Sorafenib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000208	0.00362	CcSEcCtD
Sorafenib—RAF1—thyroid gland—head and neck cancer	0.000207	0.00423	CbGeAlD
Sorafenib—Epistaxis—Fluorouracil—head and neck cancer	0.000207	0.00359	CcSEcCtD
Sorafenib—EPHB6—thyroid gland—head and neck cancer	0.000206	0.00421	CbGeAlD
Sorafenib—Hyponatraemia—Docetaxel—head and neck cancer	0.000206	0.00358	CcSEcCtD
Sorafenib—Pain in extremity—Docetaxel—head and neck cancer	0.000205	0.00356	CcSEcCtD
Sorafenib—Anorexia—Vinblastine—head and neck cancer	0.000203	0.00352	CcSEcCtD
Sorafenib—TIE1—lymph node—head and neck cancer	0.000202	0.00412	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000201	0.00349	CcSEcCtD
Sorafenib—Haemoglobin—Fluorouracil—head and neck cancer	0.000198	0.00343	CcSEcCtD
Sorafenib—KIT—trachea—head and neck cancer	0.000197	0.00403	CbGeAlD
Sorafenib—STK10—thyroid gland—head and neck cancer	0.000197	0.00403	CbGeAlD
Sorafenib—Haemorrhage—Fluorouracil—head and neck cancer	0.000197	0.00342	CcSEcCtD
Sorafenib—PDGFRA—thyroid gland—head and neck cancer	0.000195	0.00399	CbGeAlD
Sorafenib—RALBP1—head—head and neck cancer	0.000195	0.00397	CbGeAlD
Sorafenib—KDR—lymphoid tissue—head and neck cancer	0.000194	0.00396	CbGeAlD
Sorafenib—BRAF—lymph node—head and neck cancer	0.000193	0.00395	CbGeAlD
Sorafenib—PDGFRB—trachea—head and neck cancer	0.000193	0.00394	CbGeAlD
Sorafenib—Infection—Hydroxyurea—head and neck cancer	0.000193	0.00335	CcSEcCtD
Sorafenib—Dehydration—Docetaxel—head and neck cancer	0.000191	0.00331	CcSEcCtD
Sorafenib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00019	0.00331	CcSEcCtD
Sorafenib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00019	0.0033	CcSEcCtD
Sorafenib—CSF1R—lymphoid tissue—head and neck cancer	0.000189	0.00387	CbGeAlD
Sorafenib—Skin disorder—Hydroxyurea—head and neck cancer	0.000188	0.00327	CcSEcCtD
Sorafenib—Dry skin—Docetaxel—head and neck cancer	0.000188	0.00327	CcSEcCtD
Sorafenib—Abdominal pain upper—Docetaxel—head and neck cancer	0.000187	0.00325	CcSEcCtD
Sorafenib—Breast disorder—Docetaxel—head and neck cancer	0.000185	0.00322	CcSEcCtD
Sorafenib—FLT1—head—head and neck cancer	0.000185	0.00378	CbGeAlD
Sorafenib—Anorexia—Hydroxyurea—head and neck cancer	0.000185	0.00321	CcSEcCtD
Sorafenib—Decreased appetite—Vinblastine—head and neck cancer	0.000185	0.00321	CcSEcCtD
Sorafenib—EPHX2—lymph node—head and neck cancer	0.000185	0.00377	CbGeAlD
Sorafenib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000185	0.00321	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000185	0.00321	CcSEcCtD
Sorafenib—RAF1—head—head and neck cancer	0.000184	0.00375	CbGeAlD
Sorafenib—FLT3—lymph node—head and neck cancer	0.000183	0.00374	CbGeAlD
Sorafenib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000183	0.00319	CcSEcCtD
Sorafenib—EPHB6—head—head and neck cancer	0.000183	0.00373	CbGeAlD
Sorafenib—Constipation—Vinblastine—head and neck cancer	0.000182	0.00316	CcSEcCtD
Sorafenib—Pain—Vinblastine—head and neck cancer	0.000182	0.00316	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000181	0.00314	CcSEcCtD
Sorafenib—Dysphagia—Docetaxel—head and neck cancer	0.000177	0.00308	CcSEcCtD
Sorafenib—MAP2K5—thyroid gland—head and neck cancer	0.000176	0.0036	CbGeAlD
Sorafenib—KDR—thyroid gland—head and neck cancer	0.000176	0.0036	CbGeAlD
Sorafenib—Arrhythmia—Fluorouracil—head and neck cancer	0.000176	0.00305	CcSEcCtD
Sorafenib—STK10—head—head and neck cancer	0.000175	0.00357	CbGeAlD
Sorafenib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000174	0.00302	CcSEcCtD
Sorafenib—Alopecia—Fluorouracil—head and neck cancer	0.000174	0.00302	CcSEcCtD
Sorafenib—PDGFRA—head—head and neck cancer	0.000173	0.00354	CbGeAlD
Sorafenib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000173	0.00301	CcSEcCtD
Sorafenib—CSF1R—thyroid gland—head and neck cancer	0.000172	0.00351	CbGeAlD
Sorafenib—KIT—lymphoid tissue—head and neck cancer	0.000172	0.00351	CbGeAlD
Sorafenib—Erythema—Fluorouracil—head and neck cancer	0.000171	0.00297	CcSEcCtD
Sorafenib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000171	0.00297	CcSEcCtD
Sorafenib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000169	0.00293	CcSEcCtD
Sorafenib—Abdominal pain—Vinblastine—head and neck cancer	0.000168	0.00292	CcSEcCtD
Sorafenib—PDGFRB—lymphoid tissue—head and neck cancer	0.000168	0.00343	CbGeAlD
Sorafenib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000168	0.00291	CcSEcCtD
Sorafenib—Fatigue—Hydroxyurea—head and neck cancer	0.000167	0.00291	CcSEcCtD
Sorafenib—FLT4—lymph node—head and neck cancer	0.000167	0.0034	CbGeAlD
Sorafenib—Pain—Hydroxyurea—head and neck cancer	0.000166	0.00288	CcSEcCtD
Sorafenib—Constipation—Hydroxyurea—head and neck cancer	0.000166	0.00288	CcSEcCtD
Sorafenib—Neutropenia—Docetaxel—head and neck cancer	0.000166	0.00288	CcSEcCtD
Sorafenib—FGFR1—lymph node—head and neck cancer	0.000164	0.00336	CbGeAlD
Sorafenib—Weight decreased—Docetaxel—head and neck cancer	0.00016	0.00279	CcSEcCtD
Sorafenib—Pneumonia—Docetaxel—head and neck cancer	0.000159	0.00276	CcSEcCtD
Sorafenib—Anaemia—Fluorouracil—head and neck cancer	0.000158	0.00275	CcSEcCtD
Sorafenib—Infestation NOS—Docetaxel—head and neck cancer	0.000158	0.00275	CcSEcCtD
Sorafenib—Infestation—Docetaxel—head and neck cancer	0.000158	0.00275	CcSEcCtD
Sorafenib—Hypersensitivity—Vinblastine—head and neck cancer	0.000157	0.00272	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000157	0.00272	CcSEcCtD
Sorafenib—KDR—head—head and neck cancer	0.000156	0.00319	CbGeAlD
Sorafenib—MAP2K5—head—head and neck cancer	0.000156	0.00319	CbGeAlD
Sorafenib—KIT—thyroid gland—head and neck cancer	0.000156	0.00319	CbGeAlD
Sorafenib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000156	0.00271	CcSEcCtD
Sorafenib—MAP3K7—lymph node—head and neck cancer	0.000156	0.00318	CbGeAlD
Sorafenib—Renal failure—Docetaxel—head and neck cancer	0.000155	0.0027	CcSEcCtD
Sorafenib—Myocardial infarction—Docetaxel—head and neck cancer	0.000155	0.00269	CcSEcCtD
Sorafenib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000155	0.00269	CcSEcCtD
Sorafenib—Jaundice—Docetaxel—head and neck cancer	0.000154	0.00268	CcSEcCtD
Sorafenib—Stomatitis—Docetaxel—head and neck cancer	0.000154	0.00268	CcSEcCtD
Sorafenib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000153	0.00267	CcSEcCtD
Sorafenib—Leukopenia—Fluorouracil—head and neck cancer	0.000153	0.00266	CcSEcCtD
Sorafenib—Asthenia—Vinblastine—head and neck cancer	0.000153	0.00265	CcSEcCtD
Sorafenib—CSF1R—head—head and neck cancer	0.000153	0.00312	CbGeAlD
Sorafenib—PDGFRB—thyroid gland—head and neck cancer	0.000153	0.00311	CbGeAlD
Sorafenib—MKNK2—lymph node—head and neck cancer	0.000151	0.00308	CbGeAlD
Sorafenib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000149	0.0026	CcSEcCtD
Sorafenib—Epistaxis—Docetaxel—head and neck cancer	0.000149	0.00259	CcSEcCtD
Sorafenib—MKNK1—lymph node—head and neck cancer	0.000149	0.00304	CbGeAlD
Sorafenib—RET—lymph node—head and neck cancer	0.000147	0.003	CbGeAlD
Sorafenib—ABCG2—parotid gland—head and neck cancer	0.000147	0.003	CbGeAlD
Sorafenib—Myalgia—Fluorouracil—head and neck cancer	0.000146	0.00253	CcSEcCtD
Sorafenib—Diarrhoea—Vinblastine—head and neck cancer	0.000146	0.00253	CcSEcCtD
Sorafenib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000143	0.00248	CcSEcCtD
Sorafenib—Haemoglobin—Docetaxel—head and neck cancer	0.000143	0.00248	CcSEcCtD
Sorafenib—Haemorrhage—Docetaxel—head and neck cancer	0.000142	0.00247	CcSEcCtD
Sorafenib—Dizziness—Vinblastine—head and neck cancer	0.000141	0.00244	CcSEcCtD
Sorafenib—ABCG2—saliva-secreting gland—head and neck cancer	0.000141	0.00287	CbGeAlD
Sorafenib—Urinary tract disorder—Docetaxel—head and neck cancer	0.00014	0.00243	CcSEcCtD
Sorafenib—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00014	0.00243	CcSEcCtD
Sorafenib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000139	0.00242	CcSEcCtD
Sorafenib—Asthenia—Hydroxyurea—head and neck cancer	0.000139	0.00242	CcSEcCtD
Sorafenib—Urethral disorder—Docetaxel—head and neck cancer	0.000139	0.00242	CcSEcCtD
Sorafenib—Infection—Fluorouracil—head and neck cancer	0.000139	0.00241	CcSEcCtD
Sorafenib—KIT—head—head and neck cancer	0.000139	0.00283	CbGeAlD
Sorafenib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000137	0.00238	CcSEcCtD
Sorafenib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000137	0.00238	CcSEcCtD
Sorafenib—RALBP1—lymph node—head and neck cancer	0.000136	0.00278	CbGeAlD
Sorafenib—PDGFRB—head—head and neck cancer	0.000135	0.00276	CbGeAlD
Sorafenib—Vomiting—Vinblastine—head and neck cancer	0.000135	0.00235	CcSEcCtD
Sorafenib—Erythema multiforme—Docetaxel—head and neck cancer	0.000134	0.00233	CcSEcCtD
Sorafenib—Headache—Vinblastine—head and neck cancer	0.000133	0.00232	CcSEcCtD
Sorafenib—Anorexia—Fluorouracil—head and neck cancer	0.000133	0.00231	CcSEcCtD
Sorafenib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000133	0.00231	CcSEcCtD
Sorafenib—Cardiac disorder—Docetaxel—head and neck cancer	0.000132	0.00229	CcSEcCtD
Sorafenib—Flushing—Docetaxel—head and neck cancer	0.000132	0.00229	CcSEcCtD
Sorafenib—FLT1—lymph node—head and neck cancer	0.00013	0.00264	CbGeAlD
Sorafenib—RAF1—lymph node—head and neck cancer	0.000129	0.00263	CbGeAlD
Sorafenib—Angiopathy—Docetaxel—head and neck cancer	0.000129	0.00224	CcSEcCtD
Sorafenib—Dizziness—Hydroxyurea—head and neck cancer	0.000128	0.00223	CcSEcCtD
Sorafenib—Immune system disorder—Docetaxel—head and neck cancer	0.000128	0.00223	CcSEcCtD
Sorafenib—EPHB6—lymph node—head and neck cancer	0.000128	0.00261	CbGeAlD
Sorafenib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000128	0.00222	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000127	0.00221	CcSEcCtD
Sorafenib—Arrhythmia—Docetaxel—head and neck cancer	0.000127	0.0022	CcSEcCtD
Sorafenib—Nausea—Vinblastine—head and neck cancer	0.000126	0.0022	CcSEcCtD
Sorafenib—Alopecia—Docetaxel—head and neck cancer	0.000125	0.00218	CcSEcCtD
Sorafenib—Dyspnoea—Fluorouracil—head and neck cancer	0.000125	0.00216	CcSEcCtD
Sorafenib—Mental disorder—Docetaxel—head and neck cancer	0.000124	0.00216	CcSEcCtD
Sorafenib—Malnutrition—Docetaxel—head and neck cancer	0.000124	0.00215	CcSEcCtD
Sorafenib—Erythema—Docetaxel—head and neck cancer	0.000124	0.00215	CcSEcCtD
Sorafenib—Vomiting—Hydroxyurea—head and neck cancer	0.000123	0.00214	CcSEcCtD
Sorafenib—Dyspepsia—Fluorouracil—head and neck cancer	0.000123	0.00214	CcSEcCtD
Sorafenib—STK10—lymph node—head and neck cancer	0.000123	0.0025	CbGeAlD
Sorafenib—Rash—Hydroxyurea—head and neck cancer	0.000122	0.00213	CcSEcCtD
Sorafenib—Dermatitis—Hydroxyurea—head and neck cancer	0.000122	0.00212	CcSEcCtD
Sorafenib—Headache—Hydroxyurea—head and neck cancer	0.000122	0.00211	CcSEcCtD
Sorafenib—ABCC4—thyroid gland—head and neck cancer	0.000121	0.00248	CbGeAlD
Sorafenib—Decreased appetite—Fluorouracil—head and neck cancer	0.000121	0.00211	CcSEcCtD
Sorafenib—PDGFRA—lymph node—head and neck cancer	0.000121	0.00248	CbGeAlD
Sorafenib—Dysgeusia—Docetaxel—head and neck cancer	0.000121	0.0021	CcSEcCtD
Sorafenib—HTR2B—thyroid gland—head and neck cancer	0.000121	0.00247	CbGeAlD
Sorafenib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000121	0.00209	CcSEcCtD
Sorafenib—Pain—Fluorouracil—head and neck cancer	0.000119	0.00208	CcSEcCtD
Sorafenib—Muscle spasms—Docetaxel—head and neck cancer	0.000119	0.00206	CcSEcCtD
Sorafenib—Nausea—Hydroxyurea—head and neck cancer	0.000115	0.002	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—head and neck cancer	0.000114	0.00198	CcSEcCtD
Sorafenib—HTR2C—head—head and neck cancer	0.000114	0.00233	CbGeAlD
Sorafenib—Urticaria—Fluorouracil—head and neck cancer	0.000111	0.00193	CcSEcCtD
Sorafenib—Syncope—Docetaxel—head and neck cancer	0.000111	0.00192	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—head and neck cancer	0.000111	0.00192	CcSEcCtD
Sorafenib—Body temperature increased—Fluorouracil—head and neck cancer	0.00011	0.00192	CcSEcCtD
Sorafenib—MAP2K5—lymph node—head and neck cancer	0.00011	0.00224	CbGeAlD
Sorafenib—KDR—lymph node—head and neck cancer	0.00011	0.00224	CbGeAlD
Sorafenib—Loss of consciousness—Docetaxel—head and neck cancer	0.000109	0.00189	CcSEcCtD
Sorafenib—ABCC4—head—head and neck cancer	0.000108	0.0022	CbGeAlD
Sorafenib—Cough—Docetaxel—head and neck cancer	0.000108	0.00187	CcSEcCtD
Sorafenib—HTR2B—head—head and neck cancer	0.000107	0.00219	CbGeAlD
Sorafenib—CSF1R—lymph node—head and neck cancer	0.000107	0.00218	CbGeAlD
Sorafenib—Hypertension—Docetaxel—head and neck cancer	0.000107	0.00185	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—head and neck cancer	0.000105	0.00183	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—head and neck cancer	0.000105	0.00183	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000104	0.00181	CcSEcCtD
Sorafenib—Hypersensitivity—Fluorouracil—head and neck cancer	0.000103	0.00179	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—head and neck cancer	0.000103	0.00179	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—head and neck cancer	0.000101	0.00175	CcSEcCtD
Sorafenib—Infection—Docetaxel—head and neck cancer	0.0001	0.00174	CcSEcCtD
Sorafenib—Shock—Docetaxel—head and neck cancer	9.92e-05	0.00172	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—head and neck cancer	9.89e-05	0.00172	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—head and neck cancer	9.88e-05	0.00172	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—head and neck cancer	9.87e-05	0.00171	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—head and neck cancer	9.79e-05	0.0017	CcSEcCtD
Sorafenib—KIT—lymph node—head and neck cancer	9.71e-05	0.00198	CbGeAlD
Sorafenib—Anorexia—Docetaxel—head and neck cancer	9.61e-05	0.00167	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—head and neck cancer	9.56e-05	0.00166	CcSEcCtD
Sorafenib—PDGFRB—lymph node—head and neck cancer	9.48e-05	0.00193	CbGeAlD
Sorafenib—Dizziness—Fluorouracil—head and neck cancer	9.24e-05	0.0016	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	9.18e-05	0.0016	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—head and neck cancer	8.99e-05	0.00156	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—head and neck cancer	8.88e-05	0.00154	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—head and neck cancer	8.87e-05	0.00154	CcSEcCtD
Sorafenib—Rash—Fluorouracil—head and neck cancer	8.81e-05	0.00153	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—head and neck cancer	8.8e-05	0.00153	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—head and neck cancer	8.76e-05	0.00152	CcSEcCtD
Sorafenib—Headache—Fluorouracil—head and neck cancer	8.75e-05	0.00152	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—head and neck cancer	8.71e-05	0.00178	CbGeAlD
Sorafenib—Gastrointestinal disorder—Docetaxel—head and neck cancer	8.7e-05	0.00151	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—head and neck cancer	8.69e-05	0.00151	CcSEcCtD
Sorafenib—Pain—Docetaxel—head and neck cancer	8.62e-05	0.0015	CcSEcCtD
Sorafenib—Constipation—Docetaxel—head and neck cancer	8.62e-05	0.0015	CcSEcCtD
Sorafenib—ABCG2—thyroid gland—head and neck cancer	8.58e-05	0.00175	CbGeAlD
Sorafenib—Nausea—Fluorouracil—head and neck cancer	8.3e-05	0.00144	CcSEcCtD
Sorafenib—CYP1A2—thyroid gland—head and neck cancer	8.25e-05	0.00168	CbGeAlD
Sorafenib—Gastrointestinal pain—Docetaxel—head and neck cancer	8.24e-05	0.00143	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—head and neck cancer	7.97e-05	0.00138	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—head and neck cancer	7.97e-05	0.00138	CcSEcCtD
Sorafenib—ABCC4—lymph node—head and neck cancer	7.55e-05	0.00154	CbGeAlD
Sorafenib—HTR2B—lymph node—head and neck cancer	7.51e-05	0.00153	CbGeAlD
Sorafenib—Hypersensitivity—Docetaxel—head and neck cancer	7.43e-05	0.00129	CcSEcCtD
Sorafenib—ABCC2—lymph node—head and neck cancer	7.31e-05	0.00149	CbGeAlD
Sorafenib—Asthenia—Docetaxel—head and neck cancer	7.23e-05	0.00126	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—head and neck cancer	7.13e-05	0.00124	CcSEcCtD
Sorafenib—CYP2B6—head—head and neck cancer	7.02e-05	0.00143	CbGeAlD
Sorafenib—Diarrhoea—Docetaxel—head and neck cancer	6.9e-05	0.0012	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—head and neck cancer	6.67e-05	0.00116	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—head and neck cancer	6.41e-05	0.00111	CcSEcCtD
Sorafenib—Rash—Docetaxel—head and neck cancer	6.36e-05	0.0011	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—head and neck cancer	6.35e-05	0.0011	CcSEcCtD
Sorafenib—Headache—Docetaxel—head and neck cancer	6.32e-05	0.0011	CcSEcCtD
Sorafenib—ABCB1—epithelium—head and neck cancer	6.05e-05	0.00123	CbGeAlD
Sorafenib—Nausea—Docetaxel—head and neck cancer	5.99e-05	0.00104	CcSEcCtD
Sorafenib—ABCB1—trachea—head and neck cancer	5.35e-05	0.00109	CbGeAlD
Sorafenib—ABCG2—lymph node—head and neck cancer	5.33e-05	0.00109	CbGeAlD
Sorafenib—CYP2D6—head—head and neck cancer	5.22e-05	0.00106	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—head and neck cancer	4.66e-05	0.00095	CbGeAlD
Sorafenib—ABCB1—thyroid gland—head and neck cancer	4.23e-05	0.000863	CbGeAlD
Sorafenib—ABCB1—head—head and neck cancer	3.75e-05	0.000766	CbGeAlD
Sorafenib—ABCB1—lymph node—head and neck cancer	2.63e-05	0.000536	CbGeAlD
Sorafenib—MAPK11—Signaling Pathways—STAT3—head and neck cancer	2.52e-06	2.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MAPK1—head and neck cancer	2.51e-06	2.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—head and neck cancer	2.51e-06	2.46e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—head and neck cancer	2.51e-06	2.46e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.5e-06	2.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—head and neck cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—head and neck cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—head and neck cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—head and neck cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PIK3CA—head and neck cancer	2.46e-06	2.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—head and neck cancer	2.46e-06	2.41e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GPX1—head and neck cancer	2.43e-06	2.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—head and neck cancer	2.43e-06	2.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PIK3CA—head and neck cancer	2.43e-06	2.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK1—head and neck cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—head and neck cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—head and neck cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DPYD—head and neck cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PIK3CA—head and neck cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—head and neck cancer	2.41e-06	2.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	2.41e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	2.41e-06	2.36e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK3—head and neck cancer	2.4e-06	2.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—head and neck cancer	2.4e-06	2.35e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK3—head and neck cancer	2.38e-06	2.33e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—head and neck cancer	2.37e-06	2.32e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—head and neck cancer	2.37e-06	2.32e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	2.37e-06	2.32e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—head and neck cancer	2.36e-06	2.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PIK3CA—head and neck cancer	2.36e-06	2.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAPK3—head and neck cancer	2.35e-06	2.3e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—head and neck cancer	2.31e-06	2.26e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—head and neck cancer	2.31e-06	2.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—head and neck cancer	2.3e-06	2.25e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—head and neck cancer	2.3e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—YAP1—head and neck cancer	2.3e-06	2.25e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—head and neck cancer	2.29e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TYMS—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK1—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—head and neck cancer	2.29e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.28e-06	2.23e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—head and neck cancer	2.28e-06	2.23e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—head and neck cancer	2.27e-06	2.22e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—head and neck cancer	2.27e-06	2.22e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—head and neck cancer	2.27e-06	2.22e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK1—head and neck cancer	2.27e-06	2.22e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—head and neck cancer	2.27e-06	2.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—head and neck cancer	2.26e-06	2.21e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—head and neck cancer	2.26e-06	2.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—head and neck cancer	2.24e-06	2.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—head and neck cancer	2.24e-06	2.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAPK1—head and neck cancer	2.24e-06	2.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—head and neck cancer	2.24e-06	2.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—head and neck cancer	2.24e-06	2.19e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TYMS—head and neck cancer	2.24e-06	2.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.23e-06	2.19e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—head and neck cancer	2.23e-06	2.19e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—head and neck cancer	2.22e-06	2.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—head and neck cancer	2.21e-06	2.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—head and neck cancer	2.19e-06	2.15e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	2.19e-06	2.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	2.19e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—head and neck cancer	2.18e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—head and neck cancer	2.18e-06	2.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—head and neck cancer	2.17e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—head and neck cancer	2.17e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—head and neck cancer	2.17e-06	2.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK3—head and neck cancer	2.17e-06	2.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK3—head and neck cancer	2.17e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—head and neck cancer	2.16e-06	2.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—head and neck cancer	2.15e-06	2.11e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1A1—head and neck cancer	2.15e-06	2.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—head and neck cancer	2.15e-06	2.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—head and neck cancer	2.15e-06	2.1e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—head and neck cancer	2.14e-06	2.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—head and neck cancer	2.14e-06	2.09e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—head and neck cancer	2.14e-06	2.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—head and neck cancer	2.13e-06	2.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—head and neck cancer	2.12e-06	2.07e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—head and neck cancer	2.11e-06	2.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—head and neck cancer	2.1e-06	2.06e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.1e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—head and neck cancer	2.09e-06	2.05e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—head and neck cancer	2.09e-06	2.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—head and neck cancer	2.08e-06	2.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—head and neck cancer	2.07e-06	2.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—head and neck cancer	2.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—head and neck cancer	2.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—head and neck cancer	2.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—head and neck cancer	2.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—head and neck cancer	2.06e-06	2.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—head and neck cancer	2.06e-06	2.01e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—head and neck cancer	2.05e-06	2.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—head and neck cancer	2.05e-06	2.01e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—head and neck cancer	2.02e-06	1.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—head and neck cancer	2.01e-06	1.97e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—head and neck cancer	2.01e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—head and neck cancer	2e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—head and neck cancer	2e-06	1.95e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—head and neck cancer	1.99e-06	1.95e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	1.99e-06	1.95e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—head and neck cancer	1.98e-06	1.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—head and neck cancer	1.98e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—head and neck cancer	1.98e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.98e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—head and neck cancer	1.98e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.98e-06	1.93e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—head and neck cancer	1.97e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.96e-06	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—head and neck cancer	1.96e-06	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—head and neck cancer	1.96e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—head and neck cancer	1.95e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—head and neck cancer	1.95e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—head and neck cancer	1.95e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.95e-06	1.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—head and neck cancer	1.95e-06	1.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—head and neck cancer	1.94e-06	1.9e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	1.93e-06	1.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—head and neck cancer	1.93e-06	1.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—head and neck cancer	1.93e-06	1.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—head and neck cancer	1.93e-06	1.89e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—head and neck cancer	1.92e-06	1.88e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—head and neck cancer	1.9e-06	1.86e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—head and neck cancer	1.89e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—head and neck cancer	1.88e-06	1.84e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—head and neck cancer	1.86e-06	1.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—head and neck cancer	1.85e-06	1.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—head and neck cancer	1.84e-06	1.81e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.84e-06	1.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—head and neck cancer	1.84e-06	1.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—head and neck cancer	1.82e-06	1.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—head and neck cancer	1.8e-06	1.76e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—head and neck cancer	1.79e-06	1.75e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—head and neck cancer	1.79e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.79e-06	1.75e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—head and neck cancer	1.79e-06	1.75e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—head and neck cancer	1.78e-06	1.74e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.77e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.77e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.76e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—head and neck cancer	1.76e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—head and neck cancer	1.76e-06	1.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—head and neck cancer	1.76e-06	1.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—head and neck cancer	1.74e-06	1.71e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—head and neck cancer	1.73e-06	1.7e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—head and neck cancer	1.73e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.72e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—head and neck cancer	1.72e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—head and neck cancer	1.72e-06	1.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—head and neck cancer	1.7e-06	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—head and neck cancer	1.69e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—head and neck cancer	1.69e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—head and neck cancer	1.69e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	1.68e-06	1.64e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—head and neck cancer	1.68e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.67e-06	1.64e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—head and neck cancer	1.67e-06	1.64e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—head and neck cancer	1.67e-06	1.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.66e-06	1.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—head and neck cancer	1.66e-06	1.62e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—head and neck cancer	1.66e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.65e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—head and neck cancer	1.65e-06	1.61e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—head and neck cancer	1.64e-06	1.61e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—head and neck cancer	1.64e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.62e-06	1.59e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—head and neck cancer	1.62e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.61e-06	1.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—head and neck cancer	1.61e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—head and neck cancer	1.59e-06	1.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—head and neck cancer	1.57e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—head and neck cancer	1.57e-06	1.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—head and neck cancer	1.57e-06	1.53e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—head and neck cancer	1.57e-06	1.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—head and neck cancer	1.53e-06	1.49e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.5e-06	1.47e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.49e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—head and neck cancer	1.48e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—head and neck cancer	1.47e-06	1.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—head and neck cancer	1.46e-06	1.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—head and neck cancer	1.46e-06	1.43e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	1.46e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—head and neck cancer	1.44e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—head and neck cancer	1.43e-06	1.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.42e-06	1.39e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.42e-06	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—head and neck cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—head and neck cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—head and neck cancer	1.39e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—head and neck cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—head and neck cancer	1.38e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.37e-06	1.35e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—head and neck cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—head and neck cancer	1.37e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.36e-06	1.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—head and neck cancer	1.36e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—head and neck cancer	1.35e-06	1.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—head and neck cancer	1.32e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—head and neck cancer	1.3e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.29e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.28e-06	1.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—head and neck cancer	1.26e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—head and neck cancer	1.25e-06	1.22e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—head and neck cancer	1.25e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—head and neck cancer	1.25e-06	1.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—head and neck cancer	1.19e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.17e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.17e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—head and neck cancer	1.16e-06	1.14e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—head and neck cancer	1.16e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—head and neck cancer	1.15e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.14e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—head and neck cancer	1.11e-06	1.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—head and neck cancer	1.11e-06	1.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—head and neck cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.09e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—head and neck cancer	1.04e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—head and neck cancer	1.02e-06	1e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.02e-06	9.95e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—head and neck cancer	1.02e-06	9.95e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—head and neck cancer	9.95e-07	9.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—head and neck cancer	9.59e-07	9.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	8.8e-07	8.62e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—head and neck cancer	8.68e-07	8.5e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—head and neck cancer	8.5e-07	8.32e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—head and neck cancer	8.3e-07	8.13e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—head and neck cancer	7.86e-07	7.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.68e-07	7.52e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.67e-07	7.51e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	7.23e-07	7.08e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—head and neck cancer	7.19e-07	7.04e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—head and neck cancer	7.17e-07	7.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—head and neck cancer	6.7e-07	6.56e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—head and neck cancer	6.42e-07	6.29e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—head and neck cancer	6.27e-07	6.14e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	6.12e-07	6e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—head and neck cancer	5.9e-07	5.78e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—head and neck cancer	5.85e-07	5.73e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—head and neck cancer	5e-07	4.9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.73e-07	4.63e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—head and neck cancer	3.86e-07	3.78e-06	CbGpPWpGaD
